

ERROR CORRECTION FORM

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Initials:

--

Today's Date:

		2	0		
Month	Day	Year			

Infusion Date:

		2	0		
Month	Day	Year			

CIBMTR Center Number:

--	--	--	--	--	--	--	--



Chediak-Higashi Syndrome Pre-HSCT Data

Registry Use Only

Sequence Number:

Date Received:

--	--

CIBMTR Center Number:

--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Today's Date:

		2	0		
Month	Day	Year			

Date of HSCT for which this form is being completed: ☐

		2	0		
Month	Day	Year			

HSCT type: autologous allogeneic, unrelated allogeneic, related syngeneic (identical twin)

Product type: marrow PBSC cord blood other product, specify: _____

This form must be accompanied by Form 2000 – Recipient Baseline Data. All information in the box above, including the date, should be identical with the corresponding Form 2000. Information should come from an actual examination by the Transplant Center physician, or the physician who is following the recipient pre-HSCT, or abstraction of the recipient's medical records.

If this is a report of a second or subsequent transplant, check here and continue with question 10.

1. What was the date of diagnosis of Chediak-Higashi Syndrome?

Month	Day	Year			

2. Was genetic testing used to confirm the diagnosis?

- 1 yes
2 no
3 unknown

Specify genetic mutation(s) identified:

3. 1 yes 2 no CHS1 (LYST)

4. 1 yes 2 no Other mutation

5. Specify: _____

Pre-HSCT Data

Indicate which of the following manifestations of Chediak-Higashi Syndrome were present at any time prior to conditioning:

6. Leukocyte granules

- 1 present
2 absent
3 unknown

7. Neutropenia (ANC < 1 x 10⁹/L)

- 1 present
2 absent
3 unknown

8. Oculocutaneous albinism

- 1 present
2 absent
3 unknown

9. Recurrent infections

- 1 present
2 absent
3 unknown

ERROR CORRECTION FORM

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Initials:

--

Today's Date:

		2	0		
Month	Day	Year	Year		

Infusion Date:

		2	0		
Month	Day	Year	Year		

CIBMTR Center Number:

--	--	--	--	--	--	--	--

CIBMTR Center Number:

--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

10. Bleeding diathesis

- 1 present →
- 2 absent
- 3 unknown

Specify site:

- 11. 1 yes 2 no Bleeding from the GI tract
- 12. 1 yes 2 no Easy bruising
- 13. 1 yes 2 no Hematuria
- 14. 1 yes 2 no Oral bleeding
- 15. 1 yes 2 no Recurrent nosebleeds
- 16. 1 yes 2 no Other bleeding →

17. Specify site: _____

18. Neurologic dysfunction

- 1 present →
- 2 absent
- 3 unknown

Specify site:

- 19. 1 yes 2 no Abnormal gait
- 20. 1 yes 2 no Developmental delay
- 21. 1 yes 2 no Mental retardation
- 22. 1 yes 2 no Motor weakness
- 23. 1 yes 2 no Nystagmus
- 24. 1 yes 2 no Seizures
- 25. 1 yes 2 no Sensory deficits
- 26. 1 yes 2 no Other dysfunction →

27. Specify site: _____

Accelerated Phase

28. Did the recipient develop features of an accelerated phase at any time prior to the preparative regimen?

- 1 yes →
- 2 no
- 3 unknown

29. Date accelerated phase was detected:

--	--

 /

--	--

 /

--	--	--

 date unknown

Specify accelerated feature(s) present:

- 30. 1 present 2 absent 3 unknown Abnormal CSF (↑ WBC, ↑ protein)
- 31. 1 present 2 absent 3 unknown Abnormal liver function
- 32. 1 present 2 absent 3 unknown Anemia (Hb < 10 g/dL)
- 33. 1 present 2 absent 3 unknown CMV associated with accelerated phase
- 34. 1 present 2 absent 3 unknown EBV associated with accelerated phase
- 35. 1 present 2 absent 3 unknown Fevers
- 36. 1 present 2 absent 3 unknown Hemophagocytopenia (100 x 10⁹/L)
- 37. 1 present 2 absent 3 unknown Hepatomegaly
- 38. 1 present 2 absent 3 unknown Increased triglycerides
- 39. 1 present 2 absent 3 unknown Low fibrinogen
- 40. 1 present 2 absent 3 unknown Lymphadenopathy
- 41. 1 present 2 absent 3 unknown Neurologic dysfunction
- 42. 1 present 2 absent 3 unknown Neutropenia (ANC < 1 x 10⁹/L)
- 43. 1 present 2 absent 3 unknown Splenomegaly
- 44. 1 present 2 absent 3 unknown Thrombocytosis
- 45. 1 present 2 absent 3 unknown Other infection associated with accelerated phase →

46. If yes, specify other infection: _____

ERROR CORRECTION FORM

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Initials:

--	--

Today's Date:

		2	0		
Month	Day	Year	Year		

Infusion Date:

		2	0		
Month	Day	Year	Year		

CIBMTR Center Number:

--	--	--	--	--	--	--	--

CIBMTR Center Number:

--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Specific Therapies Administered Prior to the Preparative Regimen

47. Did the recipient undergo treatment for accelerated phase prior to the preparative regimen?

- 1 yes
- 2 no
- 3 unknown

Specify treatment(s) given:

- 48. 1 yes 2 no 3 unknown Acyclovir
- 49. 1 yes 2 no 3 unknown Antithymocyte globulin (ATG)
- 50. 1 yes 2 no 3 unknown Corticosteroids
- 51. 1 yes 2 no 3 unknown Etoposide (VP16)
- 52. 1 yes 2 no 3 unknown Ganciclovir (DHPG)
- 53. 1 yes 2 no 3 unknown Intrathecal methotrexate
- 54. 1 yes 2 no 3 unknown Intravenous immune globulin (IVIG)
- 55. 1 yes 2 no 3 unknown Interferon
- 56. 1 yes 2 no 3 unknown Other therapy

57. Specify other therapy:

Clinical Status Immediately Prior to the Preparative Regimen

58. Did the recipient have magnetic resonance imaging (MRI) of the brain immediately prior to the preparative regimen?

- 1 yes
- 2 no
- 3 unknown

59. Specify MRI findings:

60. Is a copy of the MRI report attached?

- 1 yes
- 2 no

61. What was the disease status of Chediak-Higashi syndrome immediately prior to the preparative regimen?

- 1 no prior accelerated phase
- 2 in remission from accelerated phase
- 3 in accelerated phase
- 4 unknown

Most Recent Evaluation of Immunologic Function Prior to the Preparative Regimen

("Absent" is defined as ≤ 10% of normal value; "decreased" is defined as 11–50% of normal value.)

	Absent	Decreased	Normal	Increased	Not tested		Month	Date of test Day	Year	Date unknown
62. Cytotoxic T-cell activity	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	63.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
64. Granulocyte chemotaxis	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	65.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
66. IgG	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	67.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
68. IgA	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	69.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
70. IgM	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	71.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
72. IgE	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	73.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
74. Natural killer cell activity	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	75.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
76. T-cell function	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	77.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>
78. T-cell numbers / subsets	1 <input type="checkbox"/>	2 <input type="checkbox"/>	3 <input type="checkbox"/>	4 <input type="checkbox"/>	5 <input type="checkbox"/>	79.	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<table border="1" style="width: 20px; height: 20px;"></table>	<input type="checkbox"/>

CIBMTR Form 2032 (CHS) v1.0 (3-4) July 2007
 Copyright © 2007 National Marrow Donor Program and
 The Medical College of Wisconsin, Inc. All rights reserved.
 For internal use only: Document F00536 version 1.0 Replaces: n/a

ERROR CORRECTION FORM

Sequence Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Initials:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Today's Date:

Month	Day	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year

Infusion Date:

Month	Day	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year	Year

CIBMTR Center Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Center Number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

CIBMTR Recipient ID:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

80. Were any other immunologic evaluations performed immediately prior to the preparative regimen?

- 1 yes
2 no
3 unknown

81. Specify test and results:

82. Did the recipient receive IVIg infusions within 2 months prior to the above immunoglobulin measurement?

- 1 yes
2 no
3 unknown

83. Signed: _____

Person completing form

Please print name: _____

Phone: (_____) _____

Fax: (_____) _____

E-mail address: _____